Thursday - September 18, 2025
Supplemental new drug application submitted to U.S. FDA for CAPLYTA (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo
July 08, 2025
NEW BRUNSWICK, New Jersey, July 8 [Category: BizHealth & Beauty] -- Johnson and Johnson posted the following news release:

* * *

Supplemental new drug application submitted to U.S. FDA for CAPLYTA(r) (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo

*

TITUSVILLE, N.J. (July 8, 2025 ) - Johnson & Johnson (NYSE:JNJ) announced today the submission of a supplemental New Drug Application . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products